Generic Name and Formulations:
Tedizolid phosphate 200mg; tabs.
Merck & Co., Inc.
Indications for SIVEXTRO:
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
≥18yrs: 200mg once daily for 6 days.
<18yrs: not established.
Not adequately evaluated in patients with neutropenia (ANC <1000 cells/mm3); consider alternate therapies. Risk of C. difficile-associated diarrhea; discontinue if suspected or confirmed. Pregnancy (Cat.C). Nursing mothers.
Tabs: May potentiate oral BCRP substrates; consider interrupting co-administered substrates esp. those with narrow therapeutic index (eg, methotrexate, topotecan); monitor if coadministration (including rosuvastatin) is necessary.
Nausea, headache, diarrhea, vomiting, dizziness.
Tabs—6 (blister pack), 30; single-use vials—10